Univercells part of Gates-backed group trying to cut polio vaccine cost

By Gareth Macdonald

- Last updated on GMT

The Bill & Melinda Gates Foundation has granted Univercells $12m (€12.5m) to develop a vaccine manufacturing platform that lowers production costs.

The firm and consortium partners Batavia Biosciences and Natrix Separations have been tasked with radically lowering costs and increasing vaccine availability and affordability in developing countries.

The project will combine Natrix’s chromatography membranes, Batavia’s production capabilities and Univercells’ manufacturing platform, which uses small footprint bioreactors capable of sustaining high cell density cultures.

Univercells told us “This compact design allows significant savings in consumables and operating cost, but also in facility design and construction costs, as the footprint and utilities required to operate this platform are drastically reduced.

“This allows our new platform to manufacture viral vaccines doses at a fraction of the current COGS, with a productivity of 40 million doses per year, and can be adapted to any viral vaccine.”

The Belgian firm told us the first tech transfer to Batavia’s manufacturing site is due to be completed in November 2018.

According to the Gates Foundation, the initial target is to establish a micro-facility for the production of inactivated polio vaccine (sIPV).

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Related suppliers

Follow us


View more